News | Cardiovascular Surgery | July 26, 2019

Keck School of Medicine Promotes Patient Diversity in Cardiac Surgery Clinical Trials

$4.5 million National Institutes of Health grant supports efforts to evaluate new surgical approaches to treat cardiovascular disease and recruit patients typically underrepresented in clinical trials

Keck School of Medicine Promotes Patient Diversity in Cardiac Surgery Clinical Trials

July 26, 2019 — A highly competitive $4.5 million grant from the National Institutes of Health (NIH) National Heart, Lung and Blood Institute (NHLBI) will support Keck School of Medicine of USC efforts to recruit patients from underrepresented populations into cardiac surgery clinical trials. The seven-year grant funds the Keck School’s ongoing research contributions to the Cardiothoracic Surgical Trials Network (CTSN), the formal NIH infrastructure for conducting major clinical trials in cardiac surgery. The grant also establishes an implementation science training program to address the critical need to develop methods to translate clinical research findings into clinical practice.

Clinical trials provide researchers with insight into how people are likely to respond to medical interventions, including surgery. Factors such as age, weight, genetics, ethnic origin and geographic location all play a role in how a person may react to different treatments. For that reason, representation of diverse patient populations in clinical trials enables researchers to better address public health concerns.

“Nearly half of Los Angeles residents are Hispanic, making the Keck School uniquely positioned to recruit a large, underrepresented population in cardiac surgery trials,” said principal investigator Michael Bowdish, M.D., MS, associate professor of surgery and preventive medicine at the Keck School. “By increasing patient diversity in cardiac surgery clinical trials, we are better suited to address cardiovascular disease, the No. 1 cause of mortality in the United States.”

The Keck School, through relationships with the Los Angeles County Department of Health Services, will recruit potential patients from areas with a large Hispanic presence, according to Bowdish. Potential patients also will be identified through the Southern California Clinical and Translational Science Institute (SC CTSI), which provides outreach and education to more than 30 predominantly Hispanic community health organizations in Los Angeles.

“Addressing the cardiovascular needs of our community is top priority,” said Vaughn A. Starnes, M.D., chair and distinguished professor of surgery and H. Russell Smith Foundation Chair for Stem Cell and Cardiovascular Thoracic Research at the Keck School. “This prestigious award provides us with valuable resources to discover novel and innovative therapies to improve the health of our Los Angeles community and beyond.”

The Keck School will collaborate with Saint Luke's Mid America Heart Institute in Kansas City, Missouri, as Linked Clinical Research Centers. This expands the patient pool for gathering and assessing data, enabling researchers to achieve stronger and more definitive research results, according to Bowdish.

In addition, the implementation science training program, under the leadership of Cecilia Patino-Sutton, M.D., Ph.D., MEd, associate professor of preventive medicine at the Keck School, will explore novel ways to translate findings from clinical research in cardiac surgery into clinical practice. The program also will leverage collaborative relationships between the Keck School, SC CTSI, the USC Gehr Family Center for Health Systems Science, and the USC Leonard D. Schaeffer Center for Health Policy and Economics, as well as the Mid America Heart Institute Cardiovascular Research Fellowship.

Keck Medicine of USC has been an active member of the CTSN since 2010. The CTSN includes more than 40 major academic medical centers across the United States and Canada, and more than 20 hospitals in Europe.

For more information: www.keck.usc.edu


Related Content

News | Cardiovascular Clinical Studies

Nov. 18, 2024 — Silence Therapeutics presented end-of-treatment data from its Phase 2 ALPACAR-360 study of zerlasiran, a ...

Home November 18, 2024
Home
News | Cardiovascular Clinical Studies

Aug. 15, 2024 — According to a new study being presented at ACC Asia 2024 in Delhi, India, drinking over 400 mg of ...

Home August 14, 2024
Home
Videos | Cardiovascular Clinical Studies

As part of DAIC's continuing Thought Leadership Series, this month Editorial Director Melinda Taschetta-Millane sits ...

Home July 30, 2024
Home
News | Cardiovascular Clinical Studies

July 25, 2024 — BioCardia, Inc., a global leader in cellular and cell-derived therapeutics for the treatment of ...

Home July 25, 2024
Home
News | Cardiovascular Clinical Studies

July 18, 2024 — Elucid, a pioneering AI medical technology company providing physicians with imaging analysis software ...

Home July 18, 2024
Home
News | Cardiovascular Clinical Studies

July 10, 2024 — CellProthera, a private company specializing in cell-based therapies for repairing ischemic tissues, and ...

Home July 10, 2024
Home
News | Cardiovascular Clinical Studies

July 9, 2024 — Microbot Medical Inc. announced the completion of the first procedure in a patient utilizing its LIBERTY ...

Home July 09, 2024
Home
News | Cardiovascular Clinical Studies

June 26, 2024 — Semaglutide, a medication initially developed for type 2 diabetes and obesity, significantly improves ...

Home June 26, 2024
Home
News | Cardiovascular Clinical Studies

June 21, 2024 — Lexicon Pharmaceuticals, Inc. announced that the peer-reviewed Journal of the American College of ...

Home June 21, 2024
Home
News | Cardiovascular Clinical Studies

June 20, 2024 — Microbot Medical Inc. announced its agreement with Brigham and Women’s Hospital (BWH), a leading ...

Home June 20, 2024
Home
Subscribe Now